ANGLE device shows promise in assessing melanoma patients

Parsortix was also shown to be superior to other methods at picking up the tell-tale signs of cancer


Researchers in Western Australia using the Parsortix liquid biopsy system have found another use for the ANGLE PLC (LON:AGL) cancer detection device.

A team at Edith Cowan University in Perth deployed the technology to monitor people with melanoma and were able to sort them into high risk and low-risk groups.

This has opened the possibility of assessing the prognosis and tailoring the treatment approach "taking into account disease status”, ANGLE investors were told.

Parsortix was also shown to be superior to other methods looked at by the Edith Cowan team at picking up the tell-tale signs of cancer assessed.

"This work clearly demonstrates the promising clinical utility of the Parsortix system for metastatic melanoma prognostication and monitoring treatment response,” said Elin Gray, an associate professor at the university.

“We now intend to progress our work with Parsortix to identify ways in which we can improve the treatment of melanoma patients."

ANGLE chief executive Andrew Newland said the latest update revealed another great example of Parsortix customers developing new cancer applications for the device.

“Melanoma is an important opportunity for future use of Parsortix," he added.

In early trading on Tuesday, shares in ANGLE added 5.8% at 73p.

 -- Adds share price --

Quick facts: ANGLE PLC

Price: 51.5 GBX

Market: AIM
Market Cap: £88.99 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...



ANGLE PLC submits its flagship Parsortix liquid biopsy diagnostic to the FDA

ANGLE PLC (LON:AGL) (OTCQX:ANPCY) CEO Andrew Newland tells Proactive the company has submitted its patent-protected, flagship Parsortix liquid biopsy diagnostic for clearance to the FDA.  Newland says this is a tremendous opportunity for ANGLE, as he says ANGLE is the first company to...

on 30/10/19

2 min read